<SEC-DOCUMENT>0001171843-18-004056.txt : 20180518
<SEC-HEADER>0001171843-18-004056.hdr.sgml : 20180518
<ACCEPTANCE-DATETIME>20180518093359
ACCESSION NUMBER:		0001171843-18-004056
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180517
FILED AS OF DATE:		20180518
DATE AS OF CHANGE:		20180518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		18845274

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_051718.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>FORM 6-K</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO RULE 13a-16 or 15d-16 OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Report on Form 6-K dated May 17, 2018</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Commission File No. 1-15024)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>Novartis AG</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Name of Registrant)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Lichtstrasse 35</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>4056 Basel</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Switzerland</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address of Principal Executive Offices)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Form 20-F:&nbsp;&#9746;</B></FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Form 40-F:&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant by furnishing the information contained
in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt"><IMG SRC="logo.jpg" ALT=""></FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 33%"><P STYLE="color: #0460A9; font-size: 10pt; font-weight: bold; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Novartis&nbsp;International&nbsp;AG<BR>
                           Novartis&nbsp;Global Communications<BR>
                           <FONT STYLE="font-weight: normal; color: windowtext">CH-4002 Basel</FONT><BR>
                           <FONT STYLE="font-weight: normal; color: windowtext">Switzerland</FONT></FONT></P>

<P STYLE="color: #0460A9; font-size: 10pt; font-weight: bold; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt">http://www.novartis.com</FONT></P>



</TD></TR>
</TABLE>
<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; background-color: Silver"><FONT STYLE="font-size: 10pt"><B>MEDIA
RELEASE &bull; COMMUNIQUE AUX MEDIAS &bull; MEDIENMITTEILUNG</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>Novartis and Amgen announce FDA approval of Aimovig<SUP>TM</SUP> (erenumab),
a novel treatment developed specifically for migraine prevention</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-style: italic; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.75pt"></TD><TD STYLE="width: 18pt">&bull;</TD><TD><FONT STYLE="font-size: 10pt">Migraine
                                         is a severe neurologic disease that profoundly impacts millions of patients in the United
                                         States</FONT></TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&bull;</TD><TD>Aimovig
                                         is the first and only FDA-approved treatment to block the calcitonin gene-related peptide
                                         receptor (CGRP-R), which plays an important role in migraine </TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&bull;</TD><TD>Aimovig
                                         was consistently shown to reduce monthly migraine days, including in more difficult to
                                         treat populations, with many patients achieving at least a 50% reduction</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"><FONT STYLE="font-size: 10pt"><I></I></FONT></P>
</P>    <P ALIGN="CENTER"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>    <P><FONT STYLE="font-size: 10pt"><B>Basel,
                                         May 17, 2018 - </B>Novartis today announced that the US Food and Drug Administration
                                         (FDA) has approved Aimovig<SUP>TM</SUP> (erenumab) for the preventive treatment of migraine
                                         in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved
                                         treatment specifically developed to prevent migraine by blocking the calcitonin gene-related
                                         peptide receptor (CGRP-R), which is believed to play a critical role in migraine. Aimovig
                                         70 mg is self-administered once monthly via Amgen's device, the SureClick<SUP>&#174;
                                         </SUP>autoinjector and does not require a loading dose. Some patients may benefit from
                                         a dosage of 140 mg once monthly.</FONT></P>    <P><FONT STYLE="font-size: 10pt">"The
                                         FDA approval of Aimovig demonstrates Novartis commitment to bringing meaningful new medicines
                                         to patients with complex neurologic diseases, like migraine," said Paul Hudson, CEO Novartis
                                         Pharmaceuticals. "Aimovig is the first therapy of its kind targeting the CGRP receptor,
                                         and has demonstrated robust efficacy across the spectrum of migraine. We look forward
                                         to working closely with Amgen in the U.S. to bring this treatment to physicians and their
                                         patients, who could now gain days of their lives back each month."</FONT></P>    <P><FONT STYLE="font-size: 10pt">In
                                         Phase II and III studies in chronic and episodic migraine, Aimovig resulted in significant
                                         reductions in monthly migraine days and use of acute migraine medications compared to
                                         placebo. These effects on monthly migraine days have been shown to be sustained for up
                                         to 15 months in an ongoing open-label extension study in episodic migraine (four to 14
                                         headache days per month). &#160;</FONT></P>    <P><FONT STYLE="font-size: 10pt">The efficacy,
                                         tolerability and safety of Aimovig has been assessed in more than 3,000 patients, including
                                         in a Phase IIIb study (LIBERTY) and an ongoing open-label extension of up to five years
                                         in duration. In LIBERTY, a dedicated study in difficult-to-treat populations - those
                                         with episodic migraine who have failed two to four prior treatments - patients taking
                                         Aimovig 140 mg had nearly three-fold higher odds of having their migraine days cut by
                                         half or more compared to placebo<SUP>1</SUP>. In clinical studies of Aimovig, the most
                                         common adverse reactions were injection site reactions and constipation.</FONT></P>    <P ALIGN="JUSTIFY"><FONT STYLE="font-size: 10pt">"Having
a treatment designed to specifically address the complex nature of migraine is an important and welcome step forward in headache
medicine. Aimovig offers self-administration with proven efficacy across a spectrum of patients, including in those who have previously
tried other preventive therapies without success," said Stewart J. Tepper, MD, Professor of Neurology at the Geisel School of
Medicine at Dartmouth Medical School. "Importantly, in clinical trials, Aimovig patients were able to start and stay on therapy
- with a discontinuation rate of two percent due to adverse events - and experienced sustained migraine prevention."</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 4</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>    <P><FONT STYLE="font-size: 10pt">Amgen
                                         and Novartis are committed to supporting the migraine community and to helping appropriate
                                         patients with affordable access to Aimovig. The Aimovig Ally<SUP>TM</SUP> product support
                                         program has been created to help patients navigate insurance coverage and identify potential
                                         access resources for those who are uninsured or underinsured.</FONT></P>    <P><FONT STYLE="font-size: 10pt">The
                                         U.S. list price of Aimovig is $575 for once monthly 70 or 140 mg single-use prefilled
                                         SureClick<SUP>&#174;</SUP> autoinjectors, or $6,900 annually. The price of Aimovig reflects
                                         the value it brings to patients and society, including the financial impact on sufferers,
                                         caregivers and employers, while also factoring in critical issues such as patient affordability,
                                         and fair and timely access.</FONT></P>    <P><FONT STYLE="font-size: 10pt">Aimovig
                                         is expected to be available to patients in the U.S. within one week.</FONT></P>    <P><FONT STYLE="font-size: 10pt">The
                                         European Medicines Agency (EMA) Marketing Authorization Application (MAA) for Aimovig
                                         is under review. Novartis expects approval in the EU in the coming months.</FONT></P>    <P><FONT STYLE="font-size: 10pt"><B>About
                                         Aimovig<SUP>TM</SUP> (erenumab)</B><BR />Aimovig is the only FDA-approved treatment specifically
                                         developed to prevent migraine by blocking the calcitonin gene related peptide receptor
                                         (CGRP-R), which is believed to play a critical role in migraine. Aimovig<SUP>TM</SUP>
                                         has been studied in several large, global, randomized, double-blind, placebo-controlled
                                         studies to assess its safety and efficacy in migraine prevention. More than 3,000 patients
                                         have participated in our overall clinical trial program across the four placebo-controlled
                                         Phase II and Phase III clinical studies and their open-label extensions.</FONT></P>     <P><FONT STYLE="font-size: 10pt"><B>About
                                         LIBERTY&#160;</B></FONT><BR /><FONT STYLE="font-size: 10pt">LIBERTY (NCT03096834) is
                                         a Phase IIIb, multicenter, randomized 12-week, double-blind, placebo-controlled study
                                         evaluating the safety and efficacy of Aimovig in patients with episodic migraine (defined
                                         in the trial as four to 14 migraine days per month at baseline) who have failed up to
                                         four prior preventive treatments for migraine<SUP>1</SUP>. In the study, 246 participants
                                         with episodic migraine who had two to four previous treatment failures were randomized
                                         to receive Aimovig 140 mg or placebo during the 12-week double-blind treatment phase.
                                         The primary endpoint was the percentage of patients with at least a 50% reduction of
                                         monthly migraine days from baseline over the last four weeks of the double-blind treatment
                                         phase of the study (weeks 9-12).&#160;The study includes an ongoing 52-week open-label
                                         extension study.</FONT></P>     <P><FONT STYLE="font-size: 10pt"><B>About Migraine</B></FONT><BR /><FONT STYLE="font-size: 10pt">Migraine
                                         is a distinct neurological disease<SUP>2</SUP>. It involves recurrent attacks of moderate
                                         to severe head pain that is typically pulsating, often unilateral and associated with
                                         nausea, vomiting and sensitivity to light, sound and odors<SUP>3</SUP>. Migraine is associated
                                         with personal pain, disability and reduced quality of life, and financial cost to society<SUP>4</SUP>.
                                         It has a profound and limiting impact on an individual's abilities to carry out everyday
                                         tasks and was reported by the World Health Organization to be one of the top 10 causes
                                         of years lived with disability for men and women<SUP>5</SUP>. It remains under-recognized
                                         and under-treated<SUP>4</SUP>,<SUP>6</SUP>. Existing preventive therapies have been repurposed
                                         from other indications and are often associated with poor tolerability and lack of efficacy,
                                         with high discontinuation rates among patients<SUP>7</SUP>.</FONT></P>     <P ALIGN="JUSTIFY"><FONT STYLE="font-size: 10pt"><B>About
                                         Novartis and Amgen Neuroscience Collaboration</B><BR />In August 2015, Novartis entered
                                         into a global collaboration with Amgen to develop and commercialize pioneering treatments
                                         in the field of migraine and Alzheimer's disease. The collaboration focuses on investigational
                                         Amgen drugs in the migraine field, including Aimovig (approved by the FDA in May 2018
                                         for the preventive treatment of migraine in adults) and AMG 301 (currently in Phase II
                                         development). In April 2017, the collaboration was expanded to include co-commercialization
                                         of Aimovig in the U.S. For the migraine program, Amgen retains exclusive commercialization
                                         rights in Japan, and Novartis has exclusive commercialization rights in Europe, Canada
                                         and rest of world. Also, the companies are collaborating in the development and commercialization
                                         of a beta-secretase 1 (BACE) inhibitor program in Alzheimer's disease. The oral therapy
                                         CNP520 (currently in Phase III for Alzheimer's disease) is the lead molecule and further
                                         compounds from both companies' pre-clinical BACE inhibitor programs may be considered
                                         as follow-on molecules.</FONT></P>

<P STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 4</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>     <P><FONT STYLE="font-size: 10pt"><B>Novartis
                                         in Neuroscience</B><BR />Novartis has a strong ongoing commitment to neuroscience and
                                         to bringing innovative treatments to patients suffering from neurological conditions
                                         where there is a high unmet need. We are committed to supporting patients and physicians
                                         in multiple disease areas, including Multiple Sclerosis (MS), Alzheimer's disease, Parkinson's
                                         disease, Epilepsy and Attention Deficit Hyperactivity Disorder, and have a promising
                                         pipeline in MS, Alzheimer's disease, migraine and specialty neurology (e.g., neuropathic
                                         pain).&#160;</FONT></P>     <P><FONT STYLE="font-size: 10pt"><B>Disclaimer</B><BR />This
                                         press release contains forward-looking statements within the meaning of the United States
                                         Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally
                                         be identified by words such as "potential," "could," "expected," "expects," "look forward,"
                                         "believed," "ongoing," "commitment," "committed," "step forward," "investigational,"
                                         "promising," "pipeline," or similar terms, or by express or implied discussions regarding
                                         potential marketing approvals, new indications or labeling for Aimovig or the other investigational
                                         or approved products described in this press release, or regarding potential future revenues
                                         from such products or the collaboration with Amgen. You should not place undue reliance
                                         on these statements. Such forward-looking statements are based on our current beliefs
                                         and expectations regarding future events, and are subject to significant known and unknown
                                         risks and uncertainties. Should one or more of these risks or uncertainties materialize,
                                         or should underlying assumptions prove incorrect, actual results may vary materially
                                         from those set forth in the forward-looking statements. There can be no guarantee that
                                         Aimovig or the other investigational or approved products described in this press release
                                         will be submitted or approved for sale or for any additional indications or labeling
                                         in any market, or at any particular time. Neither can there be any guarantee that the
                                         collaboration with Amgen will achieve any or all of its intended goals and objectives,
                                         or be commercially successful. Nor can there be any guarantee that Aimovig or the other
                                         investigational or approved products described in this press release will be commercially
                                         successful in the future. In particular, our expectations regarding such products, and
                                         the collaboration with Amgen, could be affected by, among other things, the uncertainties
                                         inherent in research and development, including clinical trial results and additional
                                         analysis of existing clinical data; regulatory actions or delays or government regulation
                                         generally; global trends toward health care cost containment, including government, payor
                                         and general public pricing and reimbursement pressures; our ability to obtain or maintain
                                         proprietary intellectual property protection; the particular prescribing preferences
                                         of physicians and patients; general political and economic conditions; safety, quality
                                         or manufacturing issues; potential or actual data security and data privacy breaches,
                                         or disruptions of our information technology systems, and other risks and factors referred
                                         to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission.
                                         Novartis is providing the information in this press release as of this date and does
                                         not undertake any obligation to update any forward-looking statements contained in this
                                         press release as a result of new information, future events or otherwise.</FONT></P>     <P><FONT STYLE="font-size: 10pt"><B>About
                                         Novartis </B><BR />Novartis provides innovative healthcare solutions that address the
                                         evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
                                         offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving
                                         generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally
                                         in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while
                                         R&amp;D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group
                                         companies employ approximately 124,000 full-time-equivalent associates. Novartis products
                                         are sold in approximately 155 countries around the world. For more information, please
                                         visit&#160;http://www.novartis.com.</FONT></P>

<P><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 4</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P><FONT STYLE="font-size: 10pt"></FONT></P>    <P><FONT STYLE="font-size: 10pt">Novartis
                                         is on Twitter. Sign up to follow @Novartis at&#160;http://twitter.com/novartis<BR />
                                         For Novartis multimedia content, please visit&#160;www.novartis.com/news/media-library<BR />
                                         For questions about the site or required registration, please contact&#160;media.relations@novartis.com</FONT></P>    <P><FONT STYLE="font-size: 10pt"><B>References</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: center">1.<BR /></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reuter, U et al. Efficacy and safety
of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study.
Emerging science abstract presented at AAN, 24 April 2018, Los Angeles.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: center">2.</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Migraine Research Foundation. Migraine
Fact Sheet. 2015. http://www.migraineresearchfoundation.org/fact-sheet.html. Accessed March 2018</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: center">3.<BR /></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">National Institute for Neurological
Disorders and Stroke. https://www.ninds.nih.gov/Disorders/All-Disorders/Migraine-Information-Page (link is external). Accessed
March 2018</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: center">4.</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">World Health Organization. Headache
disorders. http://www.who.int/mediacentre/factsheets/fs277/en/ (link is external). Accessed March 2018</FONT><BR /></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: center"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Global Health Estimates 2015: Disease burden by Cause,
Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organization; 2016.</FONT><BR /></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: center"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Diamond S et al. Patterns of Diagnosis and Acute and
Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache.
2007;47(3):355-63.</FONT><BR /></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: center"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Blumenfeld AM et al. Patterns of use and reasons for
discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international
burden of migraine study (IBMS-II). Headache. 2013 Apr;53(4):644-55.</FONT></TD>
</TR></TABLE>
<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><P STYLE="font-size: 10pt; text-align: center; margin: 0 0 0 20.9pt"><FONT STYLE="font-size: 10pt; color: Black"># #
                                               #</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; color: Black">Novartis
Media Relations</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0.6pt; margin-right: 250.65pt; margin-bottom: 0pt">Central media line: +41 61 324 2200<BR />E-mail: media.relations@novartis.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0"><FONT STYLE="font-size: 10pt; color: Black"></FONT></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR><TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-size: 10pt">Eric
                                         Althoff<BR />Novartis Global Media Relations<BR />+41 61 324 7999 (direct)<BR />+41 79
                                         593 4202 (mobile)<BR />eric.althoff@novartis.com</FONT></TD><TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-size: 10pt">Angela
                                         Fiorin<BR />Novartis Global Pharma Communications<BR />+41 61 324 8631 (direct)<BR />+41
                                         79 752 6955 (mobile)<BR />angela.fiorin@novartis.com</FONT></TD></TR></TABLE>
<P STYLE="font-size: 10pt; margin: 0.25pt 0 0"><FONT STYLE="font-size: 10pt; color: Black"></FONT></P>




<P STYLE="font-size: 10pt; margin: 0.25pt 0 0"></P>

<P STYLE="font-size: 10pt; margin: 3.7pt 0 0 23.75pt"></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="font-size: 10pt; color: Black"><B>Novartis Investor Relations</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="font-size: 10pt; color: Black">Central investor relations line: +41 61 324 7944<BR />E-mail:
                                         investor.relations@novartis.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt; color: Black">Central</FONT></TD>
    <TD STYLE="width: 18%"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt; color: Black">North America</FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: Black">Samir Shah</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: Black">+41 61 324 7944</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Richard Pulik</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+1 212 830 2448</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Pierre-Michel Bringer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 1065</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Cory Twining</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+1 212 830 2417</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Thomas Hungerbuehler</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 8425</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Isabella Zinck</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 7188</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE>
</P>
        <P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></FONT></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Novartis AG</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 17, 2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ PAUL
    PENEPENT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Penepent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head Group Financial Reporting and
    Accounting</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#F17AI9@  34T *@    @ !0$.  (
M   6   (5@$Q  (    F   (;(=I  0    !   (DIR;  $    L   0LNH<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     &YO=F%R=&ES7VQO9V]?<F=B7W!O<P!!9&]B92!);&QU<W1R871O<B!#
M0R R,#$U("A-86-I;G1O<V@I   !ZAP !P  " P   BD     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      !N &\ =@!A '( = !I ',
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MS_\ $ITHL.C$+)<./?'EK^+5^79S.69Y_0R^'PTVI2_/\K6\V?T9PI2I\/\
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M!GPBWB2[^'/B+Q=X9M[9I]2U31'M3'8 ''[U9)D?&#G<JD>I%>VU\[_M:?\
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M#?0?@UXZU+QQIC3K?Z2@T]9(# X24%FN@GRL0.&/7C->C:=^T2__  OSP/\
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M<T:RQMU5UR#^!HHJ2AP 50J@*HZ 4M%% !1110 4444 %%%% !1110 4444
M%%%% !6;J&CZ1J\(CU;2K/5(QT6[MDE _!@:**:;3NA-)JS':?I6EZ19FWTG
:3;72[<G)BM+=8E_)0!6A110VV[L$DE9'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
